Free Trial
NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

2seventy bio logo
$4.95 0.00 (0.00%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$4.93 -0.02 (-0.30%)
As of 03/14/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About 2seventy bio Stock (NASDAQ:TSVT)

Key Stats

Today's Range
$4.94
$4.96
50-Day Range
$2.30
$4.95
52-Week Range
$2.29
$5.99
Volume
2.04 million shs
Average Volume
641,192 shs
Market Capitalization
$255.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67
Consensus Rating
Hold

Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Remove Ads

2seventy bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

TSVT MarketRank™: 

2seventy bio scored higher than 62% of companies evaluated by MarketBeat, and ranked 411th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    2seventy bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about 2seventy bio's stock forecast and price target.
  • Earnings Growth

    Earnings for 2seventy bio are expected to grow in the coming year, from ($1.46) to ($0.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 2seventy bio is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 2seventy bio is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    2seventy bio has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about 2seventy bio's valuation and earnings.
  • Percentage of Shares Shorted

    10.18% of the float of 2seventy bio has been sold short.
  • Short Interest Ratio / Days to Cover

    2seventy bio has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in 2seventy bio has recently decreased by 6.61%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    2seventy bio does not currently pay a dividend.

  • Dividend Growth

    2seventy bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.18% of the float of 2seventy bio has been sold short.
  • Short Interest Ratio / Days to Cover

    2seventy bio has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in 2seventy bio has recently decreased by 6.61%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    2seventy bio has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for 2seventy bio this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 2seventy bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,350,607.00 in company stock.

  • Percentage Held by Insiders

    Only 7.20% of the stock of 2seventy bio is held by insiders.

  • Percentage Held by Institutions

    93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 2seventy bio's insider trading history.
Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

TSVT Stock News Headlines

Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More Headlines

TSVT Stock Analysis - Frequently Asked Questions

2seventy bio's stock was trading at $2.94 on January 1st, 2025. Since then, TSVT stock has increased by 68.4% and is now trading at $4.95.
View the best growth stocks for 2025 here
.

2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings data on Tuesday, March, 5th. The company reported ($1.11) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative net margin of 207.25% and a negative trailing twelve-month return on equity of 53.65%.

Top institutional investors of 2seventy bio include Newtyn Management LLC (4.91%), Bank of America Corp DE (4.88%), Regeneron Pharmaceuticals Inc. (2.43%) and Eversept Partners LP (1.95%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, Nick Leschly, Victoria Eatwell, Philip D Gregory, William D Baird III, Jessica Snow, Nicola Heffron, Marcela V Maus and Global Healthcare Master Kynam.
View institutional ownership trends
.

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
3/05/2024
Today
3/15/2025
Next Earnings (Estimated)
3/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSVT
Fax
N/A
Employees
440
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+34.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-217,570,000.00
Net Margins
-207.25%
Pretax Margin
-207.25%

Debt

Sales & Book Value

Annual Sales
$45.62 million
Price / Cash Flow
N/A
Book Value
$5.04 per share
Price / Book
0.98

Miscellaneous

Free Float
47,874,000
Market Cap
$255.36 million
Optionable
Optionable
Beta
1.73
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:TSVT) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners